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Abstract
The identiﬁcation of new components implicated in the pathogenesis of osteoarthritis (OA) might improve our understanding of the disease pro-
cess. Here, we investigated the levels of the survival of motor neuron (SMN) expression in OA cartilage considering the fundamental role of the
SMN protein in cell survival and its involvement in other stress-associated pathologies. We report that SMN expression is up-regulated in
human OA compared with normal cartilage, showing a strong correlation with the disease severity, a result conﬁrmed in vivo in an experimental
model of the disease. We further show that the prominent inﬂammatory cytokines (IL-1b, TNF-a) are critical inducers of SMN expression. This
is in marked contrast with the reported impaired levels of SMN in spinal muscular atrophy, a single inherited neuromuscular disorder character-
ized by mutations in the smn gene whereas OA is a complex disease with multiple aetiologies. While the precise functions of SMN during OA
remain to be elucidated, the conclusions of this study shed light on a novel pathophysiological pathway involved in the progression of OA,
potentially offering new targets for therapy.
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Introduction
Osteoarthritis (OA) is a degenerative disease of the whole joint [1]
that affects millions of people worldwide. Osteoarthritis is mainly
characterized by a slow, progressive destruction of major compo-
nents of the extracellular cartilage matrix, resulting from a disturbed
balance of physiological processes in chondrocytes [2], the unique
cartilage-forming cells. Various risk factors have been associated with
the incidence of OA (genetic background, ageing, trauma, obesity and
metabolic conditions) [3–6]. Several lines of evidence have demon-
strated the critical involvement of stress stimuli in the pathogenesis
of OA, including mechanical stress (loading), oxidative and biochemi-
cal stress (production of nitric oxide and of reactive oxygen species;
release of cartilage matrix degradation products, of pro-inﬂammatory
cytokines like the prominent interleukin 1 beta - IL-1b and tumour
necrosis factor alpha - TNF-a, and of matrix-degrading enzymes) [7,
8]. It is well accepted that chondrocytes are key players in the initia-
tion and progression of OA. In normal adult cartilage, they are termi-
nally differentiated cells showing basically no proliferative activity and
maintaining the matrix components (proteoglycans, type-II collagen)
under low turnover. In early OA, the chondrocyte undergo signiﬁcant
changes in their gene expression proﬁles (including through epige-
netic modiﬁcations) [9, 10], leading to transient proliferative
responses and to the synthesis of molecules that are not naturally
present in the adult cartilage (type-X, type-III, type-VI, and type-IIA
collagen, tenascin, decorin) while stopping to express the major
matrix components [10, 11]. This has been seen as an attempt at
repair but that is eventually counterbalanced by the activation of
stress pathways and molecules, by a decline in the cell responsive-
ness to reparative stimuli, and by cell senescence and degeneration,
leading to an irreversible deterioration of the cartilage architecture
[12].
Despite recent, critical advances in the identiﬁcation of OA-related
biomarkers that might allow for rapid and effective early OA diagnosis
(and for a potential development of beneﬁcial treatment options) [13,
14], the pathophysiology of this complex disorder is not yet fully
understood [15–17], showing the need to explore new aspects or
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As chondrocytes are subjected to various stress stimuli in the OA
joint, we investigated the expression proﬁles of the survival of motor
neuron (smn) gene in the cartilage during the course of OA in light of
the response of the SMN product to stress conditions (environmental
stress, heat shock and irradiation) by accumulation of the molecule in
stress granules [18] and its signiﬁcant role in oxidative stress [18–
20]. Survival of motor neuron is a central, ubiquitously expressed
protein part of macromolecular complexes, that is of fundamental
importance for the survival of all eukaryotic cells [21] and displaying
housekeeping functions in RNA metabolism (biogenesis of RNA-pro-
tein complexes, pre-mRNA splicing) [22]. For the ﬁrst time, we report
that the levels of SMN are up-regulated in human OA compared with
normal adult cartilage, showing a strong correlation with the disease
severity and an inﬂuence of key OA mediators (IL-1b and TNF-a), an
observation conﬁrmed by analysing the SMN levels in a model of
experimentally induced OA in vivo. As SMN has further been reported
for its anti-apoptotic activities [23] and its inﬂuence on transcriptional
and post-transcriptional gene regulation [24, 25], all processes rele-
vant of the pathogenesis of OA [12, 26, 27], active work is ongoing to
gain insights into the speciﬁc roles of differential SMN cartilage
expression in OA cartilage and to address the question whether SMN
up-regulation is a protective response or is causally involved in this
disease.
Materials and methods
Reagents and antibodies
All reagents were from Sigma-Aldrich (Munich, Germany) unless other-
wise indicated. The recombinant human IL-1b and human TNF-a were
purchased at R&D Systems (Wiesbaden-Nordenstadt, Germany). The
anti-SMN antibodies (H-195 and 2B1) were from Santa Cruz Biotechnol-
ogies (Santa Cruz, CA, USA).
Subjects and chondrocyte culture
Normal human adult articular cartilage was obtained from unaffected
knee joints of patients (n = 13; ages 67–72) that underwent tumour
surgery. Osteoarthritic cartilage was obtained from the joints of
patients (n = 52; ages 65–78) undergoing total knee arthroplasty. All
patients were from the Department of Orthopaedics and Orthopaedic
Surgery of the Saarland University Medical Center, Homburg, Germany.
The study was approved by the Ethics Committee of the Saarland Phy-
sicians Council. All patients provided informed consent before inclusion
in the study. Research was in compliance with the World Medical
Association Declaration of Helsinki. Cartilage explants (6.2-mm diame-
ter) and articular chondrocytes were prepared and isolated immediately
after collection as previously described [28]. Explants and cells were
cultured in DMEM, 50 lg/ml ascorbic acid, 100 U/ml penicillin G,
100 ll/ml streptomycin containing 10% foetal bovine serum (FBS) in a
humidiﬁed atmosphere with 10% CO2 at 37°C. Cells were tested after
only one passage in culture to avoid the shift in chondrocyte pheno-
type. Some parts of all the normal cartilage explants as well as cells
freshly isolated from this explants were also incubated with IL-1b or
TNF-a (each at a concentration of 10 or 100 ng/ml) for 10 days at
37°C with 10% CO2, with medium change every 3 days for further
analyses.
Animals and experimental osteoarthritis
Thirteen mature chinchilla bastard rabbits (3.5  0.5 kg weight, 7–
8 months old, with closed epiphyses and absence of joint pathology;
Charles River, Sulzfeld, Germany) were employed for the study. All pro-
cedures were approved by the Saarland University Animal Committee
according to German guidelines. Seven rabbits underwent surgical ante-
rior cruciate ligament transection (ACLT) to induce experimental OA
lesions in the knee joint cartilage. Using a medial parapatellar approach,
the patella was dislocated laterally and the knee placed in full ﬂexion.
The ACL was exposed and transected with a #15 scalpel blade. Com-
plete transection was conﬁrmed by a positive intra-operative Lachman
test. The incisions were then closed in layers. Post-operatively, the rab-
bits were allowed normal cage activity without immobilization. Six other
rabbits that were sham operated (arthrotomy only) served as controls.
The femorotibial joints of the thirteen animals were removed 4 weeks
after surgery [29] for further analyses. Isolation of articular chondro-
cytes was also performed as described above.
Histological analysis
Cartilage explants were processed and parafﬁn-embedded sections
(5 lm) were stained with safranin O to detect proteoglycans and with
haematoxylin and eosin to detect cells [28]. The severity of OA changes
was histomorphologically graded on safranin O/haematoxylin and eosin-
stained sections using the scoring method described by Mankin et al.
[30]. This grading system is based on a semi-quantitative evaluation of
the cartilage as follows: structure (0: normal; 1: surface irregularities; 2:
pannus and surface irregularities; 3: clefts to the transitional zone; 4:
clefts to the radial zone; 5: clefts to the calciﬁed zone; 6: complete dis-
organization), cells (0: normal; 1: diffuse hypercellularity; 2: cloning; 3:
hypocellularity), safranin O staining (0: normal; 1: slight reduction; 2:
moderate reduction; 3: severe reduction; 4: no dye noted) and tidemark
integrity (0: intact; 1: crossed by blood vessels).
Immunohistochemical, immunocytochemical and
histomorphometric analyses
The SMN protein was detected on histological sections of cartilage
using speciﬁc antibodies, a biotinylated secondary antibody (Vector Lab-
oratories, Gr€ unberg, Germany), and the avidin-biotin-peroxidase method
(Vector Laboratories) with diaminobenzidine as the chromogen [28]. To
control for secondary IgGs, sections were processed with omission of
the primary antibody. Samples were examined under light microscopy
(BX45 microscope; Olympus, Hamburg, Germany). The percentage of
cells positive for SMN immunoreactivity were measured at three stan-
dardized sites or using 10 serial immunohistochemical sections for each
parameter, test and replicate condition. Analysis programs included SIS
AnalySIS (Olympus), Adobe Photoshop (Adobe Systems, Unterschleiss-
heim, Germany) and Scion Image (Scion Corporation, Frederick, MD,
USA). For immunocytochemical analyses, freshly isolated chondrocytes
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4) were ﬁxed, incubated with anti-SMN antibodies and a
Texas-Red-conjugated secondary antibody (Vector Laboratories) [28].
To control for secondary IgGs, cells were processed with omission of
the primary antibody. Fluorescence was examined under a ﬂuorescent
microscope (CKX41; Olympus) using a 580-nm ﬁlter.
Biochemical analyses of the SMN protein
All cartilage explants were processed and analysed for Western blotting
analyses as previously described using 50 lg proteins [28]. Expression
was revealed with speciﬁc antibodies, horseradish peroxidase-labelled
secondary antibodies (Vector Laboratories), and the ECL Advance Wes-
tern blotting detection kit (Amersham Biosciences, Freiburg, Germany).
The SMN contents in freshly isolated chondrocytes were measured by
an SMN immunoassay as described by Kolb et al. [31] with minor mod-
iﬁcations. Brieﬂy, chondrocytes (10
4) were adhered to the bottom of the
wells of 96-well plates, ﬁxed, permeabilized with 0.1% Triton and
blocked with 20% FBS. The anti-SMN 2B1 antibody (1:500) was incu-
bated and bound antibodies were detected using a peroxidase-conju-
gated antibody (Vector Laboratories) and the Supersignal ELISA Femto
Maximum Sensitivity Substrate (Pierce, Bonn, Germany). The lumines-
cent intensity was measured using a GENios spectrophotometer/ﬂuo-
rometer (Tecan, Crailsheim, Germany). Signal background was
determined for each sample by omitting the primary antibody. A recom-
binant SMN protein (Abnova, Taipei City, Taiwan) was employed to gen-
erate a standard curve.
Isolation of RNA, cDNA synthesis and real-time
RT-PCR
RNA was prepared from all freshly isolated chondrocytes (10
6) using
the RNeasy Protect Mini Kit (Qiagen GmbH, Hilden, Germany) with an
‘on-column’ DNase digestion. Quantiﬁcation of the RNA concentrations
was performed by spectrophotometry; 1 lg RNA was converted to
cDNA using the 1st Strand cDNA Synthesis Kit for RT-PCR/AMV (Roche
Applied Science, Mannheim, Germany) exactly according to the manu-
facturer’s instructions. Real-time RT-PCR was performed with 2 ll
cDNA with the Brilliant SYBR Green QPCR Master Mix (Stratagene - Ag-
ilent, Waldbronn, Germany) to detect the transcripts for SMN (forward
primer 5′-AAAAGAAGGAAGGTGCTCACATTC-3′ and reverse primer 5′-
TGGTGTCATTTAGTGCTGCTCTATG-3′), type-II collagen (forward primer
5′-GGACTTTTCTCCCCTCTCT-3′ and reverse primer 5′-GACCCGAAGGT
CTTACAGGA-3′), and GAPDH for normalization (forward primer 5′-GAA
GGTGAAGGTCGGAGTC-3′ and reverse primer 5′-GAAGATGGTGATG
GGATTTC-3′) (all primers at 150 nM; Invitrogen GmbH, Karlsruhe, Ger-
many) [32, 33]. The reaction was carried out on a Mx3000P
  QPCR
System (Stratagene) for 10 min. 95°C, 40 9 [30 sec. 95°C, 1 min.
55°C, 30 sec. 72°C], 1 min. 95°C, and 30 sec. 55°C. The end products
were examined by gel electrophoresis. Results were captured using the
MxPro
TM QPCR Software (Stratagene).
Statistical analysis
Data are expressed as mean  SD. All human and rabbit cartilage sam-
ples were evaluated for the experiments in situ and in vitro. Data were
obtained by two individuals who were blinded with regard to the
groups. The t-test and Mann–Whitney Rank Sum Test were employed
where appropriate. Statistical analysis was performed with the SPSS
software (SPSS Inc./IBM, Chicago, IL, USA). P values < 0.05 were con-
sidered statistically signiﬁcant.
Results
SMN expression levels increase in human OA
cartilage, correlating with the disease severity
The cohort of OA patients included in the study was divided into
three groups based on a histomorphometric score established by
Mankin et al. [30] for the semi-quantitative estimation of OA extent
on safranin O-stained histological cartilage sections (Fig. 1A).
Accordingly, signiﬁcant differences could be observed between
these three groups and compared with normal donors (always
P ≤ 0.001; Fig. 1B).
An immunohistochemical analysis of SMN was performed
(Fig. 1C) to estimate the percentages of cells reactive for intracellular
SMN in all the samples (Fig. 1D). Speciﬁc immunoreactivitiy was
seen both in the superﬁcial and middle zones of the cartilage. Signiﬁ-
cant increases in the levels of SMN protein were noted both in mild
(up to 9.1-fold), moderate (up to 10.1-fold) and severe OA (up to
11.1-fold) relative to normal cartilage (always P ≤ 0.001). Also, the
levels of SMN protein signiﬁcantly increased in moderate (up to 1.5-
fold) and severe OA (up to 1.6-fold) versus mild OA cartilage (always
P ≤ 0.001) and in severe compared with moderate OA cartilage (up
to 1.6-fold, P ≤ 0.001). When the percentages of SMN-positive cells
(Fig. 1D) were combined with the corresponding, individual histologi-
cal scores per donor or patient (Fig. 1B), a strong correlation was
observed between the levels of SMN protein and the disease severity
(R
2 = 0.7215 when including normal and OA cartilage, R
2 = 0.7117
with only OA cartilage, always P ≤ 0.001; Fig. 2A).
A Western blotting analysis of protein extracts using all the nor-
mal and OA cartilage samples demonstrated a single band of about
38 kD corresponding to the SMN protein [22, 34] (Fig. 2B for repre-
sentative results). In good agreement with the ﬁndings of the immu-
nohistochemical analysis, the intensity of the SMN band was always
more intense in OA relative to normal cartilage (about 1.5-, 1.6- and
5-fold difference in mild, moderate and severe OA cartilage, respec-
tively) and increased with the disease severity (about 1.1- and 3.3-
fold in moderate and severe OA versus mild OA, respectively and
about 3.1-fold in severe compared with moderate OA).
Quantitative estimation of the amounts of SMN protein by ELISA
using freshly isolated normal and OA chondrocytes from all the sam-
ples revealed a signiﬁcant increase in the SMN concentrations both in
mild (1.5-fold, P = 0.045), moderate (3.4-fold, P ≤ 0.001) and severe
OA (6.4-fold, P = 0.002) relative to normal cartilage (Fig. 2C). Again,
the amounts of SMN signiﬁcantly increased in moderate (2.3-fold)
and severe OA (4.3-fold) versus mild OA cartilage (always P ≤ 0.001)
and in severe compared with moderate OA cartilage (1.9-fold,
P ≤ 0.001).
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Fig. 1Histological grading and survival of
motor neuron (SMN) expression in human
normal and osteoarthritis (OA) cartilage.
All samples were processed for the analy-
sis. (A) Safranin O staining of sections
from cartilage explants (representative
samples; magniﬁcation 94). (B) Grading
of OA severity on safranin O-stained histo-
logical sections from all individual ex-
plants (normal donors, n = 13, Mankin
score 0–2; mild OA patients, n = 14, Man-
kin score 2–4; moderate OA patients,
n = 22, Mankin score 5–8; severe OA
patients, n = 16, Mankin score 9–14). (C)
SMN-speciﬁc immunoreactivity on histo-
logical sections from cartilage explants
(representative samples; magniﬁcation
910). (D) Percentages of SMN-positive
cells on immunohistochemical sections
from all individual explants (8.8–14.5%,
57.6–77.0%, 59.6–85.1% and 83.3–94.5%
in normal, mild, moderate and severe OA
samples, respectively). *Statistically sig-
niﬁcant difference between groups.
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human OA chondrocytes
An immunocytochemical analysis in freshly isolated normal and OA
chondrocytes from all the samples further revealed that the SMN pro-
tein was present in discrete structures (Fig. 3A), consistent with pre-
vious reports identifying SMN as part of macromolecular structures
(gems) in distinct cell types (muscle, spinal cord and CNS tissue,
muscle, skin ﬁbroblasts) [34, 35]. An estimation of the abundance of
such SMN-speciﬁc bodies showed that the amounts of structures per
cell signiﬁcantly increased both in mild (threefold, P ≤ 0.001), mod-
erate (ﬁvefold, P ≤ 0.001) and severe OA (13-fold, P = 0.002) rela-
tive to normal cartilage (Fig. 3B). Again, the abundance of these
structures signiﬁcantly increased in moderate (1.7-fold) and severe
OA (4.3-fold) versus mild OA cartilage (always P ≤ 0.001) and in
severe compared with moderate OA cartilage (2.5-fold, P ≤ 0.001).
When the abundance of SMN-speciﬁc bodies (shown on Fig. 3B)
were combined with the corresponding, individual histological scores
per donor or patient (shown on Fig. 1B), a strong correlation was
observed between the amounts of structures and the disease severity
of (R
2 = 0.8952 when including normal and OA cartilage,
R
2 = 0.8684 with only OA cartilage, always P ≤ 0.001; Fig. 3C).
Increased SMN mRNA levels in human OA
chondrocytes
Furthermore, SMN mRNA expression was next evaluated by real-time
RT-PCR analysis in cellular extracts from all freshly isolated normal
and OA chondrocytes of the samples. In agreement with the ﬁndings
on the protein, the levels of SMN mRNA expression increased with
the disease severity and relative to normal cartilage (Fig. 3D). Accord-
ingly, a signiﬁcant increase in the intracellular ratios was noted both
in mild (up to 1.09-fold, P = 0.005), moderate (up to 1.14-fold,
P = 0.001) and severe OA (up to 1.18-fold, P ≤ 0.001) versus normal
cartilage. Also, the ratios signiﬁcantly increased in moderate (up to
1.07-fold, P = 0.016) and severe OA (up to 1.11-fold, P ≤ 0.001)
compared with mild OA cartilage and in severe relative to moderate
OA cartilage (up to 1.09-fold, P = 0.033). For comparison, the intra-
cellular type-II collagen/GAPDH ratios were also analysed, showing a
signiﬁcant up-regulation with the extent of OA and versus normal car-
tilage (Fig. 3D), possibly because of an equilibration of the phenotype
in the cell in contrast with the situation in the extracellular matrix
compartment. A signiﬁcant increase in the ratios was noted both in
mild (up to 1.12-fold), moderate (up to 1.20-fold) and severe OA (up
to 1.24-fold) compared with normal cartilage (always P ≤ 0.001).
Also, the ratios signiﬁcantly increased in moderate (up to 1.09-fold)
and severe OA (up to 1.13-fold) relative to mild OA cartilage (always
P ≤ 0.001) and in severe versus moderate OA cartilage (up to 1.05-
fold, P = 0.002). Yet, the levels of SMN mRNA expression and fold
increases noted during OA progression did not reach those attained
for type-II collagen (always P ≤ 0.001).
Effects of IL-1b and TNF-a upon cartilage SMN
expression
As IL-1b and TNF-a have been described as key mediators of OA, we
examined whether application of these cytokines induces detectable
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Fig. 2Correlation and biochemical analyses. (A) All individual values of
(Fig. 1B and D) were combined to evaluate the correlation between the
two parameters. (B) Western blotting analysis in human normal and
osteoarthritis (OA) cartilage (1: normal cartilage, 2: mild OA, 3: moder-
ate OA, 4: severe OA; representative samples). (C) Survival of motor
neuron concentrations in freshly isolated human normal and OA chon-
drocytes from all the samples (0.08  0.02, 0.11  0.02, 0.26  0.07
and 0.52  0.06 ng/mg total proteins in normal, mild, moderate and
severe OA samples, respectively). *Statistically signiﬁcant difference
between groups.
ª 2013 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
119
J. Cell. Mol. Med. Vol 18, No 1, 2014changes in the SMN immunoreactivity (%) expression proﬁles of
human normal cartilage and freshly isolated chondrocytes (Fig. 4A
and C). Treatment with IL-1b or TNF-a signiﬁcantly increased the lev-
els of SMN protein compared with normal cartilage (between 4.9- and
7.3-fold, always P ≤ 0.001) in a dose-dependent manner (1.2- or 1.5-
fold increase with IL-1b or TNF-a from 10 to 100 ng/ml, always
P ≤ 0.001), reaching the levels noted in mild OA when using concen-
trations of 10 ng/ml and those of moderate OA at 100 ng/ml. An esti-
mation of the amounts of protein in freshly isolated chondrocytes by
ELISA further showed signiﬁcant, dose-dependent increases in the
SMN concentrations when providing IL-1b or TNF-a at 10–100 ng/ml
relative to normal, untreated cells (between 1.4- and 2.3-fold differ-
ence to the normal condition and an up to 1.6-fold increase depend-
ing on the dose, always P ≤ 0.001; Fig. 4D). The histological analysis
of safranin O-stained sections conﬁrmed the effects of both cytokines
on cartilage matrix degradation (Fig. 4B).
Differential SMN expression in experimental OA
Survival of motor neuron expression was next investigated in an
in vivo model of OA induced by ACLT in rabbits to substantiate
the results of the analysis in human articular cartilage. Four weeks
after ACLT, all knees demonstrated degenerative changes on histo-
logical sections of the articular cartilage of the femoral condyles,
patellar grooves and tibial plateaus versus normal articular carti-
lage from sham-operated animals (Fig. 5A) [30], in good agree-
ment with previous ﬁndings showing that OA changes occur
rapidly in this model (within 3–8 weeks) [29]. The extent of OA in
rabbit articular cartilage (Mankin score 5–6) was comparable to a
moderate OA in human articular cartilage. Accordingly, the scores
attributed to rabbit OA cartilage were signiﬁcantly higher than
those of normal rabbit cartilage (Mankin score 0–1; P = 0.001;
Fig. 5A).
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Fig. 4Effects of IL-1b and TNF-a upon the survival of motor neuron (SMN) expression levels in human cartilage and chondrocytes. All human nor-
mal cartilage explants and cells freshly isolated from these explants were treated for 10 days with either IL-1b or TNF-a (each at either 10 or
100 ng/ml) and processed as described in the Materials and Methods. Explants and cells deﬁned with severe osteoarthritis (OA) were used as posi-
tive controls. (A) SMN-speciﬁc immunoreactivity on histological explant sections (representative samples; magniﬁcation 920). (B). Safranin O stain-
ing of histological explant sections (representative samples; magniﬁcation 92). (C) Percentages of SMN-positive cells on immunohistochemical
explant sections (all samples were processed for the analysis) (normal samples: 9.1–12.7% raising at 60.2–63.1%, 73.4–76.8%, 50.8–53.4% and
77.4–78.6% with IL-1b or TNF-a at 10 or 100 ng/ml, respectively; severe OA samples: 84.1–86.4%). (D) SMN concentrations in freshly isolated
chondrocytes (all samples were processed for the analysis) (normal samples: 0.10  0.01 ng/mg total proteins raising at 0.18  0.01,
0.22  0.02, 0.14  0.01 and 0.23  0.01 ng/mg total proteins with IL-1b or TNF-a at 10 or 100 ng/ml; severe OA samples: 0.47  0.01 ng/mg
total proteins). *Statistically signiﬁcant difference between groups.
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active for SMN in rabbit OA cartilage were signiﬁcantly higher than
those in normal rabbit cartilage (up to 11.8-fold; P ≤ 0.001; Fig. 5B).
When these percentages were combined with the corresponding his-
tomorphometric score per animal, a strong correlation was observed
between the levels of SMN immunoreactivity and the extent of experi-
mental OA (R
2 = 0.9808, P ≤ 0.001) (Fig. 5C). Western blotting
analysis of protein extracts from rabbit cartilage demonstrated a spe-
ciﬁc band of about 38 kD similar to that detected in human cartilage
[22, 34] (Fig. 5D) and that was more intense in rabbit OA cartilage
compared with normal rabbit cartilage (about twofold as for moderate
human OA). Quantitative estimation of the SMN protein in freshly iso-
lated chondrocytes by ELISA showed a signiﬁcant increase in the
SMN concentrations in rabbit OA cartilage relative to normal rabbit
cartilage (3.7-fold, P ≤ 0.001; Fig. 5D), as noted in moderate human
OA.
Discussion
Osteoarthritis is one of the most common disabling human conditions
that affects the whole joint, leading to an irreversible destruction of
the articular cartilage structure and extracellular matrix. Evidence has
accumulated that the chondrocytes, the unique cartilage-forming
cells, play central roles in the disease process, undergoing multiple
changes in their gene expression proﬁles [9, 10] in response to a vari-
ety of stress stimuli (loading, inﬂammation, oxidative stress) [7, 8].
Despite the identiﬁcation of various biomarkers of the disease, there
is a need to better characterize the key cellular and molecular mecha-
nisms that govern the initiation and progression of OA, as the patho-
physiology of this complex disorder remains poorly understood. In
this study, we speciﬁcally examined the expression patterns of the
product of the smn gene in OA cartilage in light of the implication of
SMN in stress-activated pathways [18–20] that are also observed
during the OA disease.
For the ﬁrst time to our best knowledge, we demonstrate that the
essential 38-kD cellular SMN protein is expressed both in human nor-
mal and OA cartilage in the form of discrete bodies, as previously
reported in other tissues [34, 35]. Most remarkably, we provide evi-
dence showing signiﬁcant increases in the SMN levels in human OA
versus normal adult cartilage, strongly correlating with the extent of
the disease, a result corroborated by ﬁndings in vivo in a relevant
model of experimental OA, suggesting a central, common role of
SMN between species and conﬁrming its importance during OA.
Interestingly, while modest increases were noted at the mRNA level,
more robust effects were observed at the protein level, possibly
related to a build up of the protein by post-translational modiﬁcations
[36]. Work is ongoing to analyse the proﬁles of SMN in other tissues
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Fig. 5Survival of motor neuron (SMN)
expression levels in an experimental
osteoarthritis (OA) model in vivo.( A) Saf-
ranin O staining of histological sections
from rabbit knee joint cartilage (represen-
tative samples; view of the femoral con-
dyle; magniﬁcation 94) and grading of OA
severity (all samples were processed for
the analyses). (B) SMN-speciﬁc immuno-
reactivity on sections from rabbit knee
joint cartilage (representative samples;
view of the femoral condyle; magniﬁcation
920) and percentages of SMN-positive
cells (all samples were processed for the
analyses) (normal cartilage: 7.1–13.7%;
OA cartilage: 59.7–83.8% as for moderate
human OA). (C) Correlation between the
SMN expression levels and OA severity
(combination of all values from A and B).
(D) Analysis of SMN by Western blotting
(lane 1, normal cartilage; lane 2, ACLT
cartilage; all representative samples) and
ELISA (SMN concentrations in all freshly
isolated normal and ACLT chondrocytes;
*statistically signiﬁcant difference).
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bone marrow compartment). Finally, we also demonstrate a dose-
dependent up-regulation of the SMN levels in the presence of IL-1b
and TNF-a, two prominent stress cytokines and critical mediators of
the disease pathogenesis. As a matter of fact, a number of cis-ele-
ments responsive to disease-associated cytokines (IL-6, interferons
beta and gamma - IFN-b and -c) have been already identiﬁed in the
promoter region of the smn gene [37], supporting the concept of
SMN induction under OA-speciﬁc biochemical stress. Yet, other
mediators that might also inﬂuence SMN expression should not be
excluded (mechanical and oxidative stress, adipokines, epigenetics)
[9, 38, 39], being currently under active investigation. Nevertheless,
this study provides strong evidence of the signiﬁcance of SMN regu-
lation in OA in human damaged cartilage, a ﬁnding corroborated by
the results of an analysis in vivo. To our best knowledge, this is the
ﬁrst study showing the implication of SMN during the progression of
OA, shedding light on a novel cellular component of the disease that
might allow to open new avenues of research on the onset of OA and
to identify alternative, potent targets for therapy.
Regarding the possible roles played by SMN in OA, it is interest-
ing to note that beside its housekeeping functions, SMN is a mole-
cule essential for cell survival [21], displaying anti-apoptotic
properties [23] possibly via direct interactions with Bcl-2 and p53
[40, 41], and having a key inﬂuence on transcriptional and post-tran-
scriptional gene regulation [24, 25]. As a matter of fact, several lines
of evidence have demonstrated the signiﬁcance of cell death [12] and
transcriptional regulation [26, 27] during the course of OA. The
details of the implication of SMN in these mechanisms during OA
remain to be elucidated. A comprehensive analysis in experimental
systems of SMN inhibition in OA cartilage [20] or of overexpression
in normal cartilage [19] may provide insights into the putative func-
tions of SMN in this disorder and address the question whether SMN
up-regulation is a protective response or is causally involved in the
pathogenesis of OA.
Interestingly, SMN has been originally identiﬁed as the key
determinant of spinal muscular atrophy (SMA) [42], a single inher-
ited neuromuscular disorder characterized by the degeneration of
spinal motor neurons leading to muscular paralysis with muscular
atrophy [43]. Spinal muscular atrophy is linked to recessive muta-
tions in the smn gene [44, 45], showing decreased SMN concentra-
tions in the spinal cord, skeletal muscle, liver and ﬁbroblasts of
SMA patients and a strong correlation between the disease severity
and the SMN levels [34, 46]. It is noteworthy that we observed an
up-regulation of cartilage SMN during OA whereas a dramatic
reduction was demonstrated in SMA. While SMA has been identi-
ﬁed as a single disorder linked to recessive mutations in the smn
gene, OA represents a complex disease with multiple aetiologies
(genetic background, ageing, trauma, obesity, stress environment).
It is likely that the causative mechanisms regulating smn expres-
sion in these two pathologies are different. The results of future
analyses as those described above (SMN blockade versus overex-
pression) might also help to better understand the divergence in
the SMN proﬁles between OA and SMA. Taken together, the present
ﬁndings describe SMN as a novel cellular component of the patho-
genesis of OA that may provide new targets for therapy of this
widespread, incurable disorder.
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